-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Oral glucosticoids (GCs) and proton pump inhibitors (PSPs) can cause osteoporosis fractures, and rheumatoid arthritis (RA) patients often use both drugs at the same time, so this study explores the relationship between both oral GCs and PPI and the risk of osteoporosis fractures in patients with RA.
a queue study that included patients over 50 years of age in the data chain of clinical practice studies from 1997 to 2017.
Based on drug use: current use (-lt;6 months), most recent use (7-12 months) and past use (?gt; 1 year);
the risk of osteoporosis fractures were assessed using time-related Cox proportional risk models and adjusted for lifestyle, combination and combination medications.
results were as follows: 1,411 osteoporosis fractures occurred in 12,351 RA patients (average age 68 years, 69 per cent female).
compared to the non-use of these two drugs, both oral GC and PPI are currently associated with a 1.6-fold increased risk of osteoporosis fractures (adjusted HR: 1.60, 95% CI: 1.35-1.89).
risk of osteoporosis fractures from individual oral GC or PPI was only 1.2 times higher, with statistical differences.
fracture sites were significantly associated with simultaneous oral GC and PPI.
risk of fracture does not increase with increased PPI dose or longer use time.
between simultaneous oral GC and PPI and the risk of osteoporosis fractures.
when RA patients take both oral GC and PPI, care should be taken to assess their fracture risk.
。
